A double-blind, randomised, crossover trial of two botulinum toxin type a in patients with spasticity.
<h4>Background</h4>Botulinum toxin type A (btxA) is one of the main treatment choices for patients with spasticity. Prosigne® a new released botulinum toxin serotype A may have the same effectiveness as Botox® in focal dystonia. However, there are no randomized clinical trials comparing...
Saved in:
| Main Authors: | Fábio Coelho Guarany, Paulo Dornelles Picon, Nicole Ruas Guarany, Antonio Cardoso dos Santos, Bianca Paula Mentz Chiella, Carolina Rocha Barone, Lúcia Costa Cabral Fendt, Pedro Schestatsky |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0056479&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Botulinum toxin treatment of lower extremity spasticity
by: S. E. Khat’kova, et al.
Published: (2017-11-01) -
Switox: Retrospective Analysis of Botulinum Toxin Switching in Management of Spasticity
by: Emilie Leblong, et al.
Published: (2025-02-01) -
Botulinum toxin type a for the treatment of spasticity in children with cerebral palsy
by: Dimitrijević Lidija, et al.
Published: (2007-01-01) -
Long-term efficacy of spasticity-corrective surgery and botulinum toxin injections for upper limb spasticity treatment
by: Therese Ramström, et al.
Published: (2025-05-01) -
Botulinum toxin type A chemodenervation treatment in spastic forms of cerebral palsy
by: A. L. Kurenkov, et al.
Published: (2015-02-01)